๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Fudan University454 Ruijin Hospital276 Shanghai Zhongshan Hospital163 RenJi Hospital135 Children's Hospital of Fudan University84
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Shanghai

3827 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
Clinical and Mechanistic Research on Autogenous Arteriovenous Fistula in Hemodialysis Patients
NCT07058441Arteriovenous Fistula Maturation Failure in End-stage Renal Disease
Ai Peng
Observational
100
Shanghai
2024-10-01
Recruiting
AI-Empowered Fundus Platform
NCT07424755High Myopia
Shanghai 10th People's Hospital
Observational
1,000
Shanghai
2024-10-01
By invitation
The Effect of Physical Activity Level Evaluated by Wrist-wearable Devices on Cardiovascular Disease Risk and Other Outcomes in Peritoneal Dialysis Patients
NCT06697418Peritoneal Dialysis, Cardiovascular Diseases, Myocardial Infarct, Heart Failure
Ruijin Hospital
Observational
266
Shanghai
2024-10-01
Not yet open
SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt
NCT06588179NMIBC
Fudan University
Phase 1/2
58
Shanghai
2024-10-01
Not yet open
A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC
NCT06585644Lung Cancer (NSCLC)
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
44
Shanghai
2024-10-01
Not yet open
Evaluation of TMS Visual Outcome
NCT06600932Cataract Surgery Experience
Shanghai High Myopia Study Group
Not applicable
200
Shanghai
2024-10
Not yet open
a Foundational Model for Cardiovascular Disease Diagnosis and Prediction
NCT06591923Coronary Heart Disease (CHD), Heart Failure, Arrhythmias, Valvular Heart Disease
Shanghai Zhongshan Hospital
Observational
1,000,000
Shanghai
2024-10
Not yet open
Autonomous Regulatory Monocytes (OPM Cells) for the Treatment of Diabetic Foot in a Single-arm Open-label Clinical Study
NCT06621303Diabetic Foot Ulcer
Shanghai East Hospital
Phase EARLY_PHASE1
10
Shanghai
2024-10
Recruiting
AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases
NCT06604689NSCLC (Advanced Non-small Cell Lung Cancer), Brain Metastasases
Fudan University
Observational
800
Shanghai
2024-09-30
Recruiting
Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ยฑ Camrelizumab
NCT06516289BRCA-Mutated Breast Carcinoma, HER2-negative Breast Cancer
Fudan University
Phase 2
130
Shanghai
2024-09-30
Active, closed
Pulsed-Field Ablation With/Without Electrogram Mapping
NCT07541989Non-paroxysmal Atrial Fibrillation
Xu Liu
Not applicable
300
Wuhan, Changshu, Xuzhou, Jinan, Wenling, Yuhuan, Shanghai
2024-09-30
Active, closed
Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma
NCT06447636Gastric Cancer, Gastro Esophageal Junction Cancer
Fudan University
Phase 2
20
Shanghai
2024-09-30
Recruiting
A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of pNET
NCT06592989Pancreatic Neuroendocrine Neoplasm, Sorafenib, Gefitinib
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Observational
20
Shanghai
2024-09-30
Recruiting
A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)
NCT06590246Hepatocellular Carcinoma
Shanghai AbelZeta Ltd.
Phase 1/2
121
Shanghai, Hanzhou
2024-09-30
Not yet open
Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial
NCT06620822Non Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
296
Shanghai
2024-09-30
Recruiting
Bactiseal Catheter Safety Registry Study
NCT06276543Hydrocephalus
Integra LifeSciences Corporation
Observational
200
Beijing, Guangzhou, Harbin, Wuhan, Shanghai, Chengdu
2024-09-29
Recruiting
Carbon Ion Therapy for Peripheral Non-small Cell Lung Cancer
NCT05613452Non-small Cell Lung Cancer
Shanghai Proton and Heavy Ion Center
Phase 2
43
Shanghai
2024-09-29
Recruiting
A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06589778Non-Small Cell Lung Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2
124
Shanghai
2024-09-27
Recruiting
Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma
NCT06194656Head and Neck Squamous Cell Carcinoma
Shanghai Institute Of Biological Products
Phase 2
81
Shanghai
2024-09-27
Recruiting
Neck Observation or Elective Neck Dissection in cT1N0M0 OSCC
NCT06623266Oral Cancer, Lymph Node Metastasis
Huashan Hospital
Not applicable
300
Shanghai
2024-09-26
Recruiting
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787Alzheimer Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
406
Beijing, Chongqing, Guangzhou, Shenzhen, Nanjing, Zhenjiang, Xi'an, Shanghai
2024-09-26
Recruiting
A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute Pyelonephritis
NCT06569056Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
578
Shanghai
2024-09-25
Recruiting
Magnetoencephalography in Children
NCT06668519Epilepsy, Intracranial Tumors, Cerebrovascular Disease, Autism
Children's Hospital of Fudan University
Observational
1,500
Shanghai
2024-09-25
Recruiting
Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment
NCT06563245Classical Hodgkin Lymphoma, Child, Adolescent, Young Adult
Children's Cancer Group, China
Phase 2/3
96
Shanghai
2024-09-25
Recruiting
A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
NCT06568094Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
100
Harbin, Shanghai
2024-09-25
Recruiting
The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Pancreatic Cancer.
NCT06601010Pancreatic Cancer
Ruijin Hospital
Observational
30
Shanghai
2024-09-24
Recruiting
A Study of GenSci098 in Subjects With Active Thyroid Eye Disease
NCT06569758Safety, Tolerability, GenSci098, Thyroid Eye Disease (TED)
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
76
Shanghai
2024-09-24
Recruiting
Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors
NCT06577532Pancreatic Neoplasms, Other Solid Tumors
Ruijin Hospital
Phase EARLY_PHASE1
56
Shanghai
2024-09-24
Not yet open
TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor
NCT06619886Solid Tumor, Adult, Lung Adenocarcinoma, Pancreas Cancer, Colorectal Cancer
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase EARLY_PHASE1
9
Shanghai
2024-09-24
Recruiting
Functional IOL Implantation in Patients With Epiretinal Membrane
NCT06719739Cataract, Intraocular Lens Complication, Epiretinal Membrane
Eye & ENT Hospital of Fudan University
Not applicable
90
Shanghai
2024-09-21
Recruiting
Target-specific immunoPET Imaging of Breast Cancer
NCT06715826Breast Cancer, Breast Neoplasms, Breast Cancer Metastatic
RenJi Hospital
Phase 1/2
200
Shanghai
2024-09-21
Recruiting
Combination of TURP and Standard Systemic Therapy for MPCa
NCT06655259Metastatic Prostate Cancer
Fudan University
Phase 2
200
Shanghai
2024-09-21
Recruiting
The Efficacy of Allo-HSCT in ND HR-CBF-AML
NCT06458244Acute Myeloid Leukemia
Ruijin Hospital
Observational
90
Shanghai
2024-09-21
Recruiting
U87 CAR-T in Patients With Advanced Head and Neck Tumors
NCT06614686Nasopharynx Cancer, Head and Neck Cancer
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1
20
Shanghai
2024-09-20
Active, closed
EGM Guided PFA for PerAF
NCT06729866Persistent Atrial Fibrillation
Xu Liu
Not applicable
58
Shanghai
2024-09-20
Not yet open
Neoadjuvant Moderately Hypofractionated Radiotherapy Combined with Chemotherapy and Immunotherapy for High-risk LARC
NCT06599827Rectal Cancer
Shanghai Zhongshan Hospital
Phase 2
54
Shanghai
2024-09-20
Recruiting
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
NCT06469944Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
Merck Sharp & Dohme LLC
Phase 1/2
160
Beijing, Fuzhou, Xiamen, Zhengzhou, Nanchang, Shanghai, รœrรผmqi, Hangzhou
2024-09-20
Recruiting
A Study on the Preference of Risperidone Dosage Forms
NCT06657430Schizophrenia, Bipolar Affective Disorder, Autism Spectrum Disorder, Conduct Disorder
Shanghai Mental Health Center
Observational
1,000
Shanghai
2024-09-19
Recruiting
Cadonilimab Combined With S-1 or Capecitabine as Second-line Treatment for Advanced Pancreatic Cancer
NCT06532617Pancreatic Neoplasms
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2
30
Shanghai
2024-09-19
Recruiting
A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
NCT06927466Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
Phase 1
33
Beijing, Nanchang, Shanghai, Suzhou, Wuhan, Xuzhou
2024-09-19
Recruiting
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT06635148Geographic Atrophy, Macular Degeneration
Janssen Research & Development, LLC
Phase 2/3
274
Beijing, Chengdu, Shanghai
2024-09-19
Recruiting
Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)
NCT06726421Renal Cell Carcinoma (Kidney Cancer), Kidney Cancer Metastatic, Renal Cell Carcinoma Metastatic
Sun Yat-sen University
Phase 3
252
Fuzhou, Guangzhou, Wuhan, Changchun, Chengdu, Wenzhou, Beijing, Shanghai
2024-09-18
Active, closed
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
NCT06558279Myasthenia Gravis, Ocular
argenx
Phase 3
141
Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Jinan, Nanchang, Shanghai
2024-09-18
Recruiting
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
NCT06542250B-cell Malignancies
AstraZeneca
Phase 1/2
174
Hangzhou, Shanghai
2024-09-18
Active, closed
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
NCT06559163Systemic Lupus Erythematosus
Zenas BioPharma (USA), LLC
Phase 2
190
Hefei, Beijing, Guangzhou, Shenzhen, Shijiazhuang, Nanchang, Pudong, Shanghai
2024-09-17
Recruiting
Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
NCT06567015Non-small Cell Lung Cancer (NSCLC)
Pierre Fabre Medicament
Phase 1/2
171
Shanghai, Tianjin
2024-09-17
Active, closed
A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy
NCT06537999Multifocal Motor Neuropathy
Dianthus Therapeutics
Phase 2
46
Beijing, Shanghai
2024-09-17
Recruiting
A Trial of Chinese Traditional Medicine Combining With Intradermal Acupuncture for Treating Precocious Puberty
NCT06510764Precocious Puberty, Treatment, Alternative Medicine, Acupuncture
Children's Hospital of Fudan University
Phase 3
170
Shanghai
2024-09-15
Active, closed
Evaluation on Visual Outcome of TMS
NCT06612190Visual Impairment
Evidence Based Cataract Study Group
Not applicable
300
Shanghai
2024-09-15
Recruiting
SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies
NCT06737081Anemia
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Phase 2
60
Shanghai
2024-09-14
Recruiting
Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy
NCT07067268Nasopharyngeal Cancinoma (NPC)
Fudan University
Phase 2
76
Shanghai
2024-09-14
By invitation
Efficacy and Safety of Tislelizumab Combined With Gemcitabine and Peraspartase in the Treatment of Patients With Primary Stage I-II NK/T Cell Lymphoma
NCT07450040ORR, OS, PFS
Eye & ENT Hospital of Fudan University
Observational
60
Shanghai
2024-09-12
Recruiting
FeNO Detection in Asthma Diagnosis: A New Technology Approach
NCT06852911Bronchial Asthma, Airway Disease
Novlead Inc.
Not applicable
170
Shanghai, Wuxi
2024-09-12
Recruiting
Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)
NCT06437977Stage II-III Non-small Cell Lung Cancer
Shanghai Chest Hospital
Phase 3
478
Shanghai
2024-09-12
Recruiting
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
Eli Lilly and Company
Phase 1
630
Beijing, Harbin, Shanghai
2024-09-12
By invitation
A Phase I Clinical Trial to Evaluate CU-10101 Unguent
NCT06744569Atopic Dermatitis
Cutia Therapeutics๏ผˆWuxi๏ผ‰Co.,Ltd
Phase 1
64
Shanghai
2024-09-12
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
NCT06572384Lung Diseases, Interstitial
GlaxoSmithKline
Phase 3
440
Beijing, Chengdu, Guangzhou, Hangzhou, Mianyang, Nanjing, Nanning, Shanghai
2024-09-11
Active, closed
Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT Lymphoma
NCT06583837Lymphoma, B-Cell, Marginal Zone
Fudan University
Phase 2
50
Shanghai
2024-09-10
Recruiting
A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer
NCT06692166Cervical Cancer
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 3
420
Beijing, Shanghai
2024-09-10
Recruiting
Vision Therapy Versus Prism Treatment in Small-angle Acute Acquired Concomitant Esotropia
NCT06622044Esotropia
Eye & ENT Hospital of Fudan University
Not applicable
100
Shanghai
2024-09-07
Recruiting
A Study Comparing Laparoscopic/Robotic Stoma Reduced-Port Fusion Surgery with Traditional Surgery in Patients with Temporary Ileostomy
NCT06604052Ileostomy
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
80
Shanghai
2024-09-06
Recruiting
Pinoxin for the Prevention of Radiation-Induced Skin Injury
NCT07545720Cancer Patients Undergoning Radiotherapy
Fudan University
Phase 2
202
Shanghai
2024-09-05
Recruiting
The Relationship of Psychological Stress With Therapy Efficacy and Prognosis of Gastric Cancer
NCT06786169Gastric Cancer, Gastroesophageal Junction Cancer
Fudan University
Observational
600
Shanghai
2024-09-05
Active, closed
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT06550076Plaque Psoriasis
Takeda
Phase 3
2,099
Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Wuhan, Zhenjiang, Shanghai
2024-09-04
Recruiting
A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer
NCT06631989EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
Wayshine Biopharm, Inc.
Phase 1/2
100
Hefei, Beijing, Guangzhou, Zhengzhou, Jinan, Shanghai, Chengdu, Tianjin
2024-09-04
Recruiting
Study of AXT-1003 in Subjects With Advanced Malignant Tumors.
NCT06484985Non-Hodgkin Lymphoma, Advanced Solid Tumor
Axter Therapeutics (Beijing) Co., Ltd
Phase 1
78
Beijing, Changsha, Fuzhou, Guangzhou, Shanghai
2024-09-04
Recruiting
A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients
NCT06493760Metastatic Colorectal Cancer
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 2
130
Shanghai
2024-09-03
Recruiting
Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral Nutrition
NCT06512584Short Bowel Syndrome
Chongqing Peg-Bio Biopharm Co., Ltd.
Phase 3
72
Beijing, Chongqing, Guangzhou, Changsha, Nanjing, Qingdao, Shanghai, Xiโ€™an
2024-09-03
Recruiting
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer
NCT06283719Small Cell Lung Cancer, Neuroendocrine Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2
265
Shanghai
2024-09-02
Active, closed
A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Patients With Parkinson's Disease
NCT06480461Parkinson's Disease
Shanghai Vitalgen BioPharma Co., Ltd.
Phase 1/2
39
Shanghai
2024-09-02
Recruiting
Acute EpiDural Hematoma Treated With Middle Meningeal Artery Embolization: a Randomized Trial (AEDH-MT)
NCT06292585EpiDural Hematoma, Traumatic Brain Injury
Changhai Hospital
Not applicable
194
Shanghai
2024-09-02
Recruiting
Respiratory Virome Diversity and Baseline Immunity in Healthy Individuals in Shanghai
NCT06641856Health Personnel
Ruijin Hospital
Observational
300
Shanghai
2024-09-02
Recruiting
Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
NCT06128252Gastric Cancer
Tang-Du Hospital
Not applicable
96
Wuhan, Nanjing, Shenyang, Xi'an, Chengdu, รœrรผmqi, Chongqing, Shanghai
2024-09-01
Recruiting
Continuous Effect Of Rehabilitation Training On Pulmonary Arterial Hypertension Patients
NCT07149935Pulmonary Hypertension
RenJi Hospital
Not applicable
104
Shanghai
2024-09-01
Recruiting
Transthoracic vs Transbronchial Cryoablation for Early-stage Peripheral Lung Cancer
NCT06572540Lung Cancer
Jiayuan Sun
Not applicable
110
Guangzhou, Zhengzhou, Shanghai, Chengdu, Hangzhou
2024-09-01
Recruiting
Magnetic Seizure Therapy for Psychotic Disorders
NCT06581302Psychotic Disorders
Shanghai Jiao Tong University School of Medicine
Not applicable
50
Shanghai
2024-09-01
Active, closed
Diet Intervention on Obesity Related Complication
NCT06719466Obese, Stomach Diseases
Zhang Manna
Not applicable
30
Shanghai
2024-09-01
Recruiting
Hydroxychloroquine in Children's Interstitial Lung Diseases With Genetic Causes
NCT04532346Interstitial Lung Disease, Surfactant Dysfunction
Children's Hospital of Fudan University
Phase EARLY_PHASE1
60
Shanghai
2024-09-01
Recruiting
Assessment the Effectiveness of BTVA in COPD and Ablation in Pulmonary Nodules by Pulmonary MRI
NCT07045532COPD, Lung Cancers
Shanghai Chest Hospital
Observational
100
Shanghai
2024-09-01
Not yet open
Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer
NCT06552858Ovarian Cancer
Fudan University
Phase 2
30
Shanghai
2024-09-01
Recruiting
Application of Early Bundle Management of Mechanical Ventilation to Prevent Ventilator Dependence in Children
NCT06125210Prolonged Mechanical Ventilation
Children's Hospital of Fudan University
Not applicable
150
Shanghai
2024-09-01
Active, closed
Dalpicilib-Enhanced Vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer
NCT06637150Breast Cancer
Fudan University
Phase 3
1,388
Shanghai
2024-09-01
Not yet open
Cryoablation with or Without Serplulimab in Treating Patients with Stage I-IIA Non-small Cell Lung Cancer
NCT06580665Non-small Cell Lung Cancer
Shanghai Chest Hospital
Not applicable
134
Wuhan, Nanchang, Shanghai, รœrรผmqi, Wenzhou
2024-09-01
Recruiting
Irinotecan Hydrochloride Liposome Injection (โ…ก) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer
NCT06603376Colorectal Carcinoma
Shanghai Changzheng Hospital
Phase 2
75
Shanghai
2024-09-01
Active, closed
PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
NCT06612814Breast Cancer Metastatic
Zhimin Shao
Phase 3
307
Shanghai
2024-09-01
Recruiting
Radical Hypofractionated Radiotherapy for Localized Prostate Cancer
NCT06325774Localized Prostate Cancer
Changhai Hospital
Not applicable
20
Shanghai
2024-09-01
Not yet open
JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases
NCT06567080B-cell Tumors, Autoimmune Diseases, Lupus Erythematosus, Systemic, Large B-cell Lymphoma
RenJi Hospital
Phase 1
15
Shanghai
2024-09
Not yet open
T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer
NCT06548178HER2-positive Breast Cancer
Fudan University
Phase 2
242
Shanghai
2024-09
Not yet open
CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors
NCT06567366Large B-cell Lymphoma
Ruijin Hospital
Phase 2
45
Shanghai
2024-09
Not yet open
Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for PARP Inhibitors Resistance Patients
NCT06544460Ovarian Cancer
Fudan University
Phase 2
94
Shanghai
2024-08-31
Active, closed
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
NCT06116136MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer
Servier Bio-Innovation LLC
Phase 1/2
48
Beijing, Harbin, Zhengzhou, Shenyang, Jinan, Shanghai, Hangzhou
2024-08-31
Recruiting
AR Training Versus Patching in Unilateral Amblyopia
NCT06498206Amblyopia Unilateral
Eye & ENT Hospital of Fudan University
Not applicable
114
Shanghai
2024-08-31
Not yet open
Dual-focus Soft Contact Lenses for Controlling Rapid Progressive Myopia in Young Adults
NCT06528860Myopia
Shanghai Eye Disease Prevention and Treatment Center
Not applicable
144
Shanghai
2024-08-31
Recruiting
Effect of Developmental Care on Very Low Birth Weight Infants
NCT06515574Intervention
Children's Hospital of Fudan University
Not applicable
1,600
Shanghai
2024-08-30
Recruiting
68Ga FAPI PET/CT Evaluation of Axillary Lymph Node Status After Neoadjuvant Therapy in Patients With Clinical Axillary Lymph Node Positive Breast Cancer
NCT06559371BREAST CANCER, PET/CT
Kunwei Shen
Observational
150
Shanghai
2024-08-30
Recruiting
Study With [225Ac]Ac-FL-020 in mCRPC Participants
NCT06492122Metastatic Castration-resistant Prostate Cancer
Full-Life Technologies UK Limited
Phase 1
50
Beijing, Shanghai
2024-08-30
Recruiting
Live Birth Rate Between ICSI and AOA and ICSI Alone in Patients With Severe Teratospermia
NCT06561451Male Infertility, Teratospermia
ShangHai Ji Ai Genetics & IVF Institute
Not applicable
208
Shanghai
2024-08-30
Recruiting
Peginterferon ฮฑ-2b Injection for Hydroxyurea Resistant or Intolerant ET
NCT06552429Essential Thrombocythemia
Xiamen Amoytop Biotech Co., Ltd.
Phase 2
27
Beijing, Fujian, Guangzhou, Harbin, Henan, Shanghai, Zhejiang
2024-08-29
Recruiting
A Study on the Efficacy of Atezolizumab Combined with Chemotherapy
NCT06780826Lung Cancer, Small Cell
Shanghai Pulmonary Hospital, Shanghai, China
Observational
1,430
Shanghai
2024-08-28
Recruiting
A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
NCT06493864Breast Cancer, Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
21
Shanghai
2024-08-26
Rows per page Showing 2201–2300 of 3827
Previous 21 22 23 24 25 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai?page=23

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3,827 of those studies with a site in Shanghai.

How many clinical trials are recruiting in Shanghai?

2,393 of the 3,827 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 737 have not yet opened recruitment, 588 are active but closed to new participants, and 109 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.